SK281583B6 - Spôsob detekcie malígnych a premalígnych zmien - Google Patents

Spôsob detekcie malígnych a premalígnych zmien Download PDF

Info

Publication number
SK281583B6
SK281583B6 SK738-93A SK73893A SK281583B6 SK 281583 B6 SK281583 B6 SK 281583B6 SK 73893 A SK73893 A SK 73893A SK 281583 B6 SK281583 B6 SK 281583B6
Authority
SK
Slovakia
Prior art keywords
syndecan
cells
sample
content
malignant
Prior art date
Application number
SK738-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK73893A3 (en
Inventor
Markku Tapani Jalkanen
Pirjo Leena Kyllikki Inki
Jarkko Kirjavainen
Sirpa Marianne Leppa
Sakari Markku Mali
Original Assignee
Biotie Therapies Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27093707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK281583(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Corp. filed Critical Biotie Therapies Corp.
Publication of SK73893A3 publication Critical patent/SK73893A3/sk
Publication of SK281583B6 publication Critical patent/SK281583B6/sk

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
SK738-93A 1991-01-15 1991-12-19 Spôsob detekcie malígnych a premalígnych zmien SK281583B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64120991A 1991-01-15 1991-01-15
US72133091A 1991-07-01 1991-07-01
PCT/FI1991/000399 WO1992013274A1 (en) 1991-01-15 1991-12-19 Detection of syndecan content in biological materials such as tissues and body fluids for indications of malignant transformations of cells

Publications (2)

Publication Number Publication Date
SK73893A3 SK73893A3 (en) 1993-11-10
SK281583B6 true SK281583B6 (sk) 2001-05-10

Family

ID=27093707

Family Applications (1)

Application Number Title Priority Date Filing Date
SK738-93A SK281583B6 (sk) 1991-01-15 1991-12-19 Spôsob detekcie malígnych a premalígnych zmien

Country Status (23)

Country Link
US (1) US5422243A (de)
EP (2) EP0816851A3 (de)
JP (1) JP3103377B2 (de)
KR (1) KR0162670B1 (de)
AT (1) ATE166157T1 (de)
AU (1) AU650936B2 (de)
BG (1) BG61625B1 (de)
CA (1) CA2100077C (de)
CZ (1) CZ282203B6 (de)
DE (1) DE69129417T2 (de)
DK (1) DK0569367T3 (de)
ES (1) ES2116331T3 (de)
FI (1) FI104347B (de)
HU (1) HU215778B (de)
IE (2) IE920107A1 (de)
NO (1) NO314604B1 (de)
NZ (1) NZ241273A (de)
PL (1) PL168188B1 (de)
PT (1) PT100008B (de)
RU (1) RU2139540C1 (de)
SK (1) SK281583B6 (de)
WO (1) WO1992013274A1 (de)
ZA (1) ZA92271B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
ES2154290T3 (es) * 1992-12-01 2001-04-01 Biotie Therapies Corp Estimulacion de la diferenciacion celular por sindecano.
US6017727A (en) * 1994-03-07 2000-01-25 Biotie Therapies Ltd. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
GB9519490D0 (en) * 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
US6385546B1 (en) 1996-11-15 2002-05-07 Rutgers, The University Of New Jersey Stabilizing and destabilizing proteins
JP4287588B2 (ja) * 1997-08-12 2009-07-01 レアト ベー．フェー． 作用因子の形質転換能力定量
EP1146903A4 (de) * 1998-10-16 2005-02-16 Univ California Glypicane zur detektion und behandlung humaner karzinome
US6998232B1 (en) * 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
WO2001077682A1 (fr) * 2000-04-10 2001-10-18 Institut Bioorganicheskoi Khimii Imeni Akademikov M.M. Shemyakina I Ju. A. Ovchinnikova Rossiisskoi Akademii Nauk Anticorps diriges contre le facteur hldf, procedes de fabrication correspondants, peptides avec des capacites antigeniques et a hydrolyse hk et procede de diagnostic de l'etat anaplasique de cellules humaines
WO2002086084A2 (en) * 2001-04-04 2002-10-31 Quark Biotech, Inc. Sequence characteristics of bladder cancer
KR100694804B1 (ko) * 2005-05-18 2007-03-14 아주대학교산학협력단 작은 헤어핀 ｒｎａ 분자를 포함하는 자궁 내막암 치료또는 예방용 조성물 및 그를 이용한 자궁 내막암 치료 또는예방 방법
US8347890B2 (en) * 2006-06-19 2013-01-08 Insono Therapeutics, Inc. Automated tissue retention system
WO2009105624A2 (en) * 2008-02-21 2009-08-27 Massachusetts Institute Of Technology Simultaneous delivery of receptors and/or co-receptors for growth factor stability and activity
GB0803272D0 (en) * 2008-02-22 2008-04-02 Smith & Nephew Ultrasound and tissue repair

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3511199A1 (de) * 1985-03-28 1986-10-02 Hoechst Ag, 6230 Frankfurt Verfahren zur immunologischen bestimmung von heparansulfat-proteoglykan, verfahren zur herstellung bzw. reinigung von dafuer geeignetem heparansulfat-proteoglykan aus basalmembran-haltigen geweben
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
JPH02156898A (ja) * 1988-12-08 1990-06-15 Seikagaku Kogyo Co Ltd 抗低密度型ヘパラン硫酸プロテオグリカンモノクローン抗体、それを産生するハイブリドーマおよびこのモノクローン抗体を用いる低密度型ヘパラン硫酸プロテオグリカンの検出方法
WO1990007712A1 (de) * 1988-12-23 1990-07-12 Bissendorf Peptide Gmbh Antigen, assoziiert mit degenerativen erscheinungen des zentralen nervensystems (zns), dagegen gerichtete antikörper sowie verfahren zur diagnose von dysfunktionen des zns
WO1990012033A1 (en) * 1989-03-29 1990-10-18 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
WO1993005167A1 (en) * 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses

Also Published As

Publication number Publication date
EP0569367A1 (de) 1993-11-18
ATE166157T1 (de) 1998-05-15
FI104347B1 (fi) 1999-12-31
NO932552D0 (no) 1993-07-14
FI933211A (fi) 1993-09-15
FI933211A0 (fi) 1993-07-15
PT100008B (pt) 1999-06-30
BG97950A (bg) 1995-02-28
EP0816851A3 (de) 2000-08-23
RU2139540C1 (ru) 1999-10-10
NO314604B1 (no) 2003-04-14
WO1992013274A1 (en) 1992-08-06
EP0569367B1 (de) 1998-05-13
AU9071391A (en) 1992-08-27
DE69129417D1 (de) 1998-06-18
BG61625B1 (bg) 1998-01-30
HU215778B (hu) 1999-02-01
HU9302030D0 (en) 1993-11-29
CA2100077A1 (en) 1992-07-16
HUT67587A (en) 1995-04-28
CA2100077C (en) 1999-11-16
JP3103377B2 (ja) 2000-10-30
EP0816851A2 (de) 1998-01-07
FI104347B (fi) 1999-12-31
DK0569367T3 (da) 1998-10-07
PT100008A (pt) 1993-02-26
KR0162670B1 (ko) 1999-05-01
IE920107A1 (en) 1992-07-15
SK73893A3 (en) 1993-11-10
NO932552L (no) 1993-07-14
ZA92271B (en) 1992-10-28
NZ241273A (en) 1993-10-26
AU650936B2 (en) 1994-07-07
CZ137293A3 (en) 1994-01-19
DE69129417T2 (de) 1998-11-05
IE990011A1 (en) 2000-11-01
ES2116331T3 (es) 1998-07-16
PL168188B1 (pl) 1996-01-31
JPH06504616A (ja) 1994-05-26
US5422243A (en) 1995-06-06
CZ282203B6 (cs) 1997-05-14

Similar Documents

Publication Publication Date Title
Iruela-Arispe et al. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium.
DE60034594T2 (de) Diagnose von malignen neoplasmen
Castellani et al. The fibronectin isoform containing the ED‐B oncofetal domain: a marker of angiogenesis
Pinzani et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells
Svee et al. Acute lung injury fibroblast migration and invasion of a fibrin matrix is mediated by CD44.
SK281583B6 (sk) Spôsob detekcie malígnych a premalígnych zmien
Asadi et al. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia
Krishna et al. 9-O-Acetylation of sialomucins: a novel marker of murine CD4 T cells that is regulated during maturation and activation
Haglund et al. Expression of laminin in pancreatic neoplasms and in chronic pancreatitis
Cannistra et al. Functional heterogeneity of CD44 molecules in ovarian cancer cell lines.
Letamendía et al. Endoglin, a component of the TGF‐β receptor system, is a differentiation marker of human choriocarcinoma cells
Linnala et al. Transforming growth factor-beta regulates the expression of fibronectin and tenascin in BEAS 2B human bronchial epithelial cells.
Aziz et al. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL)
Das et al. Upregulation of keratinocyte growth factor in cyclosporin A‐induced gingival overgrowth
US20080267955A1 (en) Frizzled 9 as tumor marker
CA2410515A1 (en) Method of identifying and/or isolating stem cells
JP4297689B2 (ja) 抗原の発現量を定量する方法
JP2005526233A (ja) 乳房上皮細胞によるソライアシン発現を用いた方法
Yasuda et al. Differential expression of the α1 type VIII collagen gene by smooth muscle cells from atherosclerotic plaques of apolipoprotein-E-deficient mice
Staiano-Coico et al. PAI-1 gene expression is growth state-regulated in cultured human epidermal keratinocytes during progression to confluence and postwounding
Charpin et al. ELAM selectin expression in breast carcinomas detected by automated and quantitative immunohistochemical assays.
Tiger et al. Absence of laminin α1 chain in the skeletal muscle of dystrophic dy/dy mice
Ravn et al. Estrogen-and progesterone receptors in normal cycling endometrium as studied by end-point titration
Orui et al. Proliferation and apoptosis of follicular lymphocytes: relationship to follicular dendritic cell‐associated clusters
Charpin et al. VLA2 integrin expression in breast carcinomas evaluated by automated and quantitative immunohistochemistry